Anti-FGFR2/CD332 Antibody

R1310-10

Product Type:	Rabbit polyclonal IgG, primary antibodies
Species reactivity:	Human
Applications:	WB, IF-Cell, IHC-P, FC
Molecular Wt:	~100 kDa

Description: Fibroblast growth factor receptor 2 (FGFR2) also known as CD332 has two naturally occurring isoforms FGFR2IIIb and FGFR2IIIc, created by splicing of the third immunoglobulin-like domain. FGFR2IIIb is predominantly found in ectoderm derived tissues and endothelial organ lining, i.e. skin and internal organs. FGFR2 has important roles in embryonic development and tissue repair, especially bone and blood vessels. Like the other members of the Fibroblast growth factor receptor family, these receptors signal by binding to their ligand and dimerisation (pairing of receptors), which causes the tyrosine kinase domains to initiate a cascade of intracellular signals. As mentioned, FGFR2 mutations are associated with craniosynostosis syndromes, which are skull malformations caused by premature fusion of cranial sutures and other disease features according to the mutation itself.

Immunogen: Recombinant protein within human FGFR2/CD332 aa 600-750 / 821.

Positive control: MCF-7, K562, Jurkat

Subcellular location: Cell membrane, golgi apparatus, cytoplasmic vesicle

Database links: SwissProt: P21802 Human

Recommended Dilutions:

WB	1:2,000
IF-Cell	1:200

Storage Buffer: 1*PBS (pH7.4), 0.2% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Storage Instruction: Shipped at 4℃. Store at +4℃ short term (1-2 weeks). It is recommended to aliquot into single-use upon delivery. Store at -20℃ long term.

Purity: Protein A affinity purified.

Images



Fig1: Western blot analysis on cell lysates using anti- CD332 rabbit polyclonal antibodies.



Fig2: ICC staining CD332 in SK-BR-3 cells (green). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS and counterstained with DAPI in order to highlight the nucleus (blue).

Note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE".

Background References

1. "Fibroblast growth factor signalling: from development to cancer." Turner N., Grose R. Nat. Rev. Cancer 10:116-129(2010)
2. "FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies." Katoh M. J. Invest. Dermatol. 129:1861-1867(2009)
3. "Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation." Kaabeche K., Lemonnier J., Le Mee S., Caverzasio J., Marie P.J. J. Biol. Chem. 279:36259-36267(2004)